Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 18/20 | 0.66 |
| ▸ | SCN1A | P35498 | 12/20 | 0.66 |
| ▸ | SCN8A | Q9UQD0 | 12/20 | 0.66 |
| ▸ | SCN1B | Q07699 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19011638 | 0.88 | SCN5A (0.66) | SCN5ASCN1ASCN8ASCN1BCYP3A4 | |
| SCHEMBL20182483 | 0.86 | SCN5A (0.62) | SCN5ASCN1ASCN8ASCN1BCYP3A4 | |
| SCHEMBL20095581 | 0.82 | SCN5A (0.59) | SCN5ASCN1ASCN8ASCN1BCYP3A4 | |
| SCHEMBL20096109 | 0.82 | SCN5A (0.62) | SCN5ASCN1ASCN8ASCN1B | |
| SCHEMBL19401003 | 0.82 | SCN9A (0.69) | SCN5ACYP3A4SCN9A | |
| SCHEMBL18983164 | 0.81 | SCN5A (0.69) | SCN5ASCN1ACYP3A4SCN9A | |
| SCHEMBL20256510 | 0.81 | SCN5A (0.66) | SCN5ASCN1ASCN8ACYP3A4SCN9A | |
| SCHEMBL28528479 | 0.81 | SCN5A (0.74) | SCN5ASCN1ASCN8ACYP3A4SCN9A | |
| SCHEMBL28521476 | 0.81 | SCN5A (0.74) | SCN5ASCN1ASCN8ACYP3A4SCN9A | |
| SCHEMBL28521474 | 0.81 | SCN5A (0.74) | SCN5ASCN1ASCN8ACYP3A4SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968210-B2 | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME CORP. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200131167-A1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968210-B2 | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels | TRPV1, SCN1A, SCN7A | SCN5A 17/4885SCN1A 2/4885SCN8A 11/4885 |
| US-20200131167-A1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | TRPV1, SCN1A, SCN7A | SCN5A 17/4885SCN1A 2/4885SCN8A 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.